论文部分内容阅读
目的:研究表皮生长因子受体(epidermal growth factor receptor,EGFR)在子宫内膜癌组织中的表达及其基因突变情况。方法:取江西省肿瘤医院及南昌大学第二附属医院2007年1月至2011年4月期间的子宫内膜石蜡包埋组织104例,其中子宫内膜癌组织56例、非典型增生子宫内膜组织18例、正常子宫内膜组织30例,利用免疫组化检测上述各组织中EGFR蛋白的表达,PCR法扩增子宫内膜癌或正常子宫内膜组织中EGFR基因外显子19、21序列并测序检测其突变情况。结果:子宫内膜癌组织中EGFR的阳性表达率高于正常子宫内膜[73.2%(41/56)vs 30.0%(9/30),P<0.01]及非典型增生子宫内膜[73.2%(41/56)vs 44.4%(8/18),P<0.05]。进一步分析表明:G3级子宫内膜癌中EGFR的阳性表达率明显高于G1级[81.8%(9/11)vs 66.7%(12/18),P<0.01]及G2级[81.8%(9/11)vs 74.1%(20/27),P<0.05],在肌层浸润>1/2组中的阳性表达率也明显高于肌层浸润≤1/2组[86.8%(33/38)vs 44.4%(8/18),P<0.01]。但EGFR的表达与子宫内膜癌的FIGO分期、有无淋巴结转移无明显相关性。发现1例子宫内膜癌组织中,EGFR基因外显子19有G2281A突变,而外显子21无突变。结论:EGFR的阳性表达率与子宫内膜癌的组织学分级及肌层浸润深度有关,子宫内膜癌组中存在EGFR外显子19的G2281A点突变。
Objective: To study the expression of epidermal growth factor receptor (EGFR) in endometrial carcinoma and its gene mutation. Methods: 104 cases of endometrial paraffin-embedded tissues from Jiangxi Cancer Hospital and the Second Affiliated Hospital of Nanchang University from January 2007 to April 2011 were collected, including 56 cases of endometrial carcinoma, atypical hyperplasia endometrium 18 cases of normal tissue and 30 cases of normal endometrial tissue. The expression of EGFR protein was detected by immunohistochemistry, and the exon 19 and 21 of EGFR gene in endometrial carcinoma or normal endometrial tissue were amplified by PCR And sequenced to detect the mutation. Results: The positive rate of EGFR in endometrial carcinoma was significantly higher than that in normal endometrium (73.2%, 41/56 vs 30.0%, P <0.01) and in atypical hyperplasia (73.2% (41/56) vs 44.4% (8/18), P <0.05]. Further analysis showed that the positive expression rate of EGFR in G3 endometrial carcinoma was significantly higher than that in G1 grade [81.8% (9/11) vs 66.7% (12/18), P <0.01] and G2 grade [81.8% (9) / 11) vs 74.1% (20/27), P <0.05]. The positive rate of myometrial infiltration> 1/2 group was also significantly higher than that of myometrial invasion ≤1 / 2 [86.8% (33/38 ) vs 44.4% (8/18), P <0.01]. However, there was no significant correlation between the expression of EGFR and the FIGO staging of endometrial cancer with or without lymph node metastasis. Found in 1 case of endometrial cancer, EGFR gene exon 19 G2281A mutation, while exon 21 without mutation. Conclusion: The positive expression rate of EGFR is related to the histological grade and the depth of myometrial invasion in endometrial carcinoma. The G2281A point mutation of EGFR exon 19 exists in the endometrial carcinoma group.